Journals / Acta Oncologica Turcica / 2014 / Cilt: 47 Sayı: 1

Peritoneovaginal Fistula during Intraperitoneal Chemotherapy of Epithelial Ovarian Carcinoma

Epitelyal Over Karsinomunda İntraperitoneal Kemoterapi sırasında oluşan Peritonovajinal Fistül

Pages
22–23
Publication Date
2014-08-21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although the significant improvement on survival, IP chemotherapy should be given carefully

📌 3 Key Takeaways

🎯
Objective & Hypothesis:chemotherapy showed 16-month OS advantage for optimally resected stage III EOC (1).
📊
Key Findings & Data:However, catheter-related complications are common reasons (13-40%) for discontinuation of IP treatment.
💡
Conclusion & Impact:Although the significant improvement on survival, IP chemotherapy should be given carefully
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İntraperitoneal tedavi · over neoplazmları · peritoneovajinal fistül

Abstract

chemotherapy showed 16-month OS advantage for optimally resected stage III EOC (1). However, catheter-related complications are common reasons (13-40%) for discontinuation of IP treatment. These are abdominal pain, bleeding, blockage, leakage, movement, malfunction, and/or access problems (2). Peritoneovaginal fistula is a rare complication of IP treatment, “leaky vaginal cuff” was the reason for discontinuation of treatment 2 of the 71 patients in a study (3). Although the significant improvement on survival, IP chemotherapy should be given carefully

Özet

Address for Correspondence: Uzm. Dr. Havva Yeşil Çınkır Ankara Onkoloji Hastanesi, Tıbbi Onkoloji Bölümü Ankara - Türkiye e-mail: [email protected] Available at www.actaoncologicaturcica.com

🔖

Cite This Article

DEMİRCİ, U., ÇINKIR, H. Y., YALÇIN, B. (2014). Peritoneovaginal Fistula during Intraperitoneal Chemotherapy of Epithelial Ovarian Carcinoma. Acta Oncologica Turcica, Cilt: 47 Sayı: 1, 22–23. https://ajindex.com/articles/978777

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal Cisplatin and Paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
  2. Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008;108:342-7
  3. Zeimet AG, Reimer D, Radl AC, et al. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res. 2009;29:2803-8.